Ketamine Analgesic Effect by Continuous Intravenous Infusion in Refractory Cancer Pain: Considerations about the Clinical Research in Palliative Care

2012 ◽  
Vol 15 (3) ◽  
pp. 287-293 ◽  
Author(s):  
Sébastien Salas ◽  
Matthieu Frasca ◽  
Brigitte Planchet-Barraud ◽  
Benoît Burucoa ◽  
Monique Pascal ◽  
...  
Keyword(s):  
Palliative Care ◽  
Cancer Pain ◽  
Clinical Research ◽  
Intravenous Infusion ◽  
Analgesic Effect ◽  
Continuous Intravenous Infusion

Dexmedetomidine for dyspnoea

2020 ◽  
pp. bmjspcare-2020-002334
Author(s):  
Akiko Mano ◽  
Tomohiro Murata ◽  
Kazuma Date ◽  
Mitsuhiro Kawata ◽  
Miyuki Sato ◽  
...  
Keyword(s):  
Palliative Care ◽  
Intensive Care ◽  
Intravenous Infusion ◽  
Symptom Management ◽  
Care Setting ◽  
Terminally Ill ◽  
Pulmonary Haemorrhage ◽  
Continuous Intravenous Infusion ◽  
First Line ◽  
Palliative Care Setting

Dexmedetomidine is a selective α2-adrenoreceptor agonist with a broad range of effects, including easily controllable sedation, analgesia and anxiolysis. Because of these favorable features, it has replaced traditional sedatives, such as benzodiazepines, and is becoming the first-line sedative for the patients in intensive care units. Terminally ill patients often need sedatives for symptom management, especially for dyspnoea. However, the use of dexmedetomidine in a palliative care setting has rarely been recognised to date. We experienced a patient nearing the end of life due to uncontrollable pulmonary haemorrhage on ventilator, whose dyspnoea was successfully managed by dexmedetomidine in addition to continuous intravenous infusion of oxycodone.

Continuous Intravenous Infusion of Ketamine and Lidocaine as Adjuvant Analgesics in a 5-Year-Old Patient with Neuropathic Cancer Pain

2012 ◽  
Vol 15 (6) ◽  
pp. 719-722 ◽  
Author(s):  
Teruyuki Kajiume ◽  
Yasuhiko Sera ◽  
Ryuichi Nakanuno ◽  
Taemi Ogura ◽  
Shuhei Karakawa ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Intravenous Infusion ◽  
Continuous Intravenous Infusion

High Transdermal Fentanyl Requirements in a Patient with Chronic Cancer Pain

1993 ◽  
Vol 27 (5) ◽  
pp. 575-578 ◽  
Author(s):  
Victoria Tutag Lehr ◽  
Elizabeth A. Renaud
Keyword(s):  
Cancer Pain ◽  
Intravenous Infusion ◽  
Pain Control ◽  
Continuous Intravenous Infusion ◽  
Patient Controlled Analgesia ◽  
Transdermal Fentanyl ◽  
Dosage Requirement ◽  
Chronic Cancer Pain ◽  
Analgesic Regimen ◽  
Patient Reported

OBJECTIVE: To report a case of high transdermal fentanyl dosage requirements in a patient with chronic cancer pain. DATA SOURCES: Clinical studies, review articles, and relevant laboratory information. CASE SUMMARY: A 42-year-old woman with cervical cancer was admitted for control of her pain. Her outpatient analgesic regimen was a continuous intravenous infusion of morphine sulfate (MS) via an ambulatory infusion device. Upon admission, supplemental doses of intravenous MS were administered in an effort to eliminate the pain. Transdermal fentanyl therapy was initiated on hospital day 1 at 100 μg/h and the MS continuous intravenous infusion dosage was increased. Over the next four days, the patient experienced episodes of inadequate pain control and the transdermal fentanyl dosage was increased in increments of 100 μg/h. On hospital day 4 the MS continuous infusion was converted to patient-controlled analgesia (PCA). The patient reported acceptable pain control with a regimen of transdermal fentanyl 500 μg/h and MS via PCA and she was discharged home on hospital day 7. CONCLUSIONS: This patient's high transdermal fentanyl dosage requirement was related to disease progression. She experienced an acute pain episode that may have been effectively managed by increasing the dosage of her continuous intravenous MS infusion.

scholarly journals Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy

2021 ◽  
Vol 63 (1) ◽  
Author(s):  
Janaina Maria Xavier Corrêa ◽  
Raquel Vieira Niella ◽  
Jéssica Natália Silva de Oliveira ◽  
Alex Costa Silva Junior ◽  
Claire Souza da Costa Marques ◽  
...  
Keyword(s):  
Postoperative Pain ◽  
Intravenous Infusion ◽  
Analgesic Effect ◽  
Multimodal Analgesia ◽  
Anesthesia Induction ◽  
Intravenous Bolus ◽  
Continuous Intravenous Infusion ◽  
Rescue Analgesia ◽  
Analgesic Drugs ◽  
Pain Scores

Abstract Background Multimodal analgesia consists of the combination of analgesic drugs at low doses to act in different places along the path of pain. Studies with continuous infusion of analgesic drugs in cats are not common. This study aimed to evaluate the analgesic effect of maropitant, lidocaine and ketamine alone or in combination (intravenous bolus + subsequent continuous intravenous infusion) in the management of acute postoperative pain in cats undergoing ovariohysterectomy. Seventy healthy cats undergoing an ovariohysterectomy received a standard anesthetic protocol consisting of acepromazine and morphine, propofol (anesthesia induction), and isoflurane (anesthesia maintenance). The animals were stratified into seven groups (n = 10 in each group): control (CG), maropitant (MG), lidocaine (LG), ketamine (KG), maropitant + lidocaine (LMG), maropitant + ketamine (KMG), and maropitant + lidocaine + ketamine (LKMG). All drugs were injected first as an intravenous bolus and then by continuous intravenous infusion. During surgery, esophageal temperature, respiratory rate, heart rate, oxygen saturation, expired isoflurane concentration, and partial pressure of carbon dioxide at the end of expiration were evaluated at 7 time points. Postoperative pain was evaluated for 6 h after extubation using the visual analogue scale and the UNESP-Botucatu multidimensional composite pain scale for assessing postoperative pain in cats. Results Adverse effects related to maropitant, lidocaine and ketamine infusion were not observed. Pain scores were lower in the MG, KG and LG groups when compared to the CG group using both scales. Although pain scores were also lower in all combination groups than CG, more animals in these groups required rescue analgesia compared to MG. This indicates that the postoperative analgesic effect of all drugs, either alone or in combination, confers analgesia, although the combinations did not promote greater analgesia. Conclusions Continuous intravenous infusion of maropitant, lidocaine, and ketamine alone induces postoperative analgesic effect in cats undergoing ovariohysterectomy, but combinations of these drugs did not increase the analgesic effect. No adverse effect was observed with any drug or their combination.

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Intravenous Infusion ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Continuous Intravenous Infusion ◽  
Endoscopic Retrograde ◽  
Pancreatic Enzyme Secretion

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

Sign in / Sign up

Export Citation Format

Share Document